ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1580

Abnormal High Density Lipoproteins in Synovial Fluid from Patients with Rheumatoid Arthritis Compared to Patients with Non-Inflammatory Arthritis

Christina Charles-Schoeman1, Yuen Yin Lee2, Ani Shahbazian1, David Meriwether3, Peter Kim2 and Srinivasa T. Reddy4, 1Medicine-Rheumatology, University of California Los Angeles, Los Angeles, CA, 2Medicine- Rheumatology, University of California Los Angeles, Los Angeles, CA, 3Medicine- Cardiology, University of California Los Angeles, Los Angeles, CA, 4Medicine-Cardiology, University of California Los Angeles, Los Angeles, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Cholesterol, rheumatoid arthritis (RA) and synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:   High levels of rheumatoid arthritis (RA) disease activity have been
associated with abnormal function of circulating high density lipoproteins
(HDL) and increased cardiovascular risk.  Oxidative modifications to the HDL
particle by enzymes such as myeloperoxidase (MPO) occur in atherosclerotic
plaques of non-RA patients and adversely affect HDL function.  In the current
work, we evaluated the oxidant environment and anti-oxidant function of HDL in
synovial fluid (SF) from RA patients compared to patients with non-inflammatory
arthritis (NIA).

 

Methods: HDL
was isolated from synovial fluid of 10 RA patients and 11 NIA patients by
dextran bead precipitation.  HDL’s anti-oxidant function was measured by a cell
free assay as described previously (A&R 2009; 60(10): 2870-9). MPO
and paraoxonase 1 (PON1) activity (using both paraoxonase and arylesterase
assays), were measured in SF by previously published assays with minor
modifications (
ARD 2012 Jul;71(7):1157-62, A&R 2012; 64(6):1828-37).  Oxidation products of arachidonic acid and
linoleic acid including 5 hydroxyeicosatetraenoic acid (HETE), 12-HETE,
15-HETE, 9-hydroxyoctadecadienoic acid (HODE) and 13-HODE were measured in
synovial fluid by mass spectrometry as described previously with minor
modifications (
Drug Metab Lett. 2010; 4(3): 139-48). Total and HDL
cholesterol (HDL-C) levels in SF were determined by standard methods.

 

Results: HDL
in SF from RA patients had significantly worse anti-inflammatory, anti-oxidant
function as measured by a higher mean HDL inflammatory index (HII) compared to
SF HDL from patients with NIA (see table).  RA SF had significantly higher MPO
activity and higher levels of 15-HETE which were most strongly correlated with
SF macrophage cell counts (r values= 0.7 and 0.6 respectively, p values
<0.05) and showed trends for correlations with the HII (r = 0.5 and 0.3
respectively, p values =0.2).  Higher levels of total cholesterol, HDL-C, and
PON1 activity were noted in RA SF compared to NIA SF (see table).

 

Conclusion: HDL
is increased in RA SF and is pro-inflammatory and pro-oxidant compared to HDL
from NIA SF. These findings suggest a potential mechanism by which circulating
HDL in active RA patients lose their protective capacity by exposure to the
pro-oxidant joint milieu, linking high RA disease activity to abnormal HDL
function, and potentially increased CV risk.

 

 

Group

HII

Age (yrs)

F    (%)

SF total

WBC Ct.

SF Neut.

Ct.

SF Mac.

Ct.

MPO activity

 (ng/ml)

HDL-C (mg/dL)

TC (mg/dL)

PON activity

 (U/ml)

Aryl

activity

(U/ml)

5HETE (ng/ml SF)

12HETE (ng/ml SF)

15HETE(ng/ml SF)

9HODE (ng/ml SF)

13HODE  (ng/ml SF)

RA SF

2.1 ± 1.9*

55±  13

60

15409 ±  6153*

11840±7000*

2074±1490*

74 ± 48*

18 ±

10

59 ±

17*

412 ± 150*

93± 43*

0.44± 0.33

0.12± 0.07

0.37± 0.07*

1.31± 1.70

4.15± 4.20

NIA SF

0.5 ± 0.1

69 ±  19

55

617 ±  496

120 ± 177

247 ± 135

0.9 ± 0.6

12 ±

 7

26 ±

 17

122± 129

27± 10

0.57± 0.68

0.12± 0.05

0.26± 0.11

0.63± 0.36

2.02± 1.20

HII=HDL
Inflammatory Index; F = Female; WBC = White blood cell; Ct = count; Neut =
neutrophil; Mac = macrophage; TC = total cholesterol; Aryl = Arylesterase. *p
value < 0.05 compared to NIA.

 


Disclosure: C. Charles-Schoeman, None; Y. Y. Lee, None; A. Shahbazian, None; D. Meriwether, None; P. Kim, None; S. T. Reddy, None.

To cite this abstract in AMA style:

Charles-Schoeman C, Lee YY, Shahbazian A, Meriwether D, Kim P, Reddy ST. Abnormal High Density Lipoproteins in Synovial Fluid from Patients with Rheumatoid Arthritis Compared to Patients with Non-Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/abnormal-high-density-lipoproteins-in-synovial-fluid-from-patients-with-rheumatoid-arthritis-compared-to-patients-with-non-inflammatory-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/abnormal-high-density-lipoproteins-in-synovial-fluid-from-patients-with-rheumatoid-arthritis-compared-to-patients-with-non-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology